Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 168
interventional 136
Observational 27
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 41
Drug|placebo 25
Biological 19
Biological|placebo 15
Biological|Drug 6
Dietary Supplement 4
Dietary Supplement|placebo 4
Procedure 4
Device 3
Drug|Other 3
Biological|Drug|placebo 2
Drug|Procedure 2
Other 2
Biological|Other 1
Device|Drug|placebo 1
Device|Procedure 1
Diagnostic Test 1
Other|placebo 1
Other|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 56
United States|Canada 16
NA 14
Canada 13
Japan 3
Denmark 2
France 2
Hong Kong 2
Norway 2
United Kingdom 2
Austria|Belgium|Croatia|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|Ireland|Italy|Poland|Portugal|Romania|Russian Federation|Slovenia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Austria|France|Greece|Italy|Poland|Russian Federation|United Kingdom 1
Austria|Hungary 1
Belgium 1
Bulgaria 1
Bulgaria|Germany|Romania|Serbia 1
China 1
Croatia 1
Croatia|United States|Argentina|Belgium|Brazil|Canada|Chile|Czechia|Greece|Hungary|Israel|Korea, Republic of|Romania|Slovakia 1
Germany|France|United States|Belgium|Canada|Italy|Spain|Sweden|United Kingdom 1
Poland|United States|Belgium|Canada|France|Germany|Hungary|Italy|Romania|Spain 1
Sweden 1
United States|Argentina|Australia|Belarus|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Germany|Greece|Hungary|Korea, Republic of|Mexico|New Zealand|Peru|Poland|Portugal|Romania|Russian Federation|Spain 1
United States|Argentina|Australia|Belgium|Bulgaria|Canada|Chile|Colombia|Czechia|Finland|France|Germany|Hungary|Japan|Korea, Republic of|Peru|Poland|Portugal|Slovakia|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Brazil|Colombia|Czechia|Germany|Hungary|Malaysia|Mexico|Norway|Poland|Portugal|Romania|South Africa|Spain|Sweden|United Kingdom 1
United States|Australia|Brazil|Canada|France|Germany|Italy|Netherlands|Peru|Poland|Romania|Spain 1
United States|Belarus|Belgium|Canada|Czechia|Estonia|France|Georgia|Germany|Israel|Latvia|Lithuania|Mexico|Peru|Romania|Spain 1
United States|Belgium|Canada|Germany|Spain|Switzerland 1
United States|Bulgaria|Canada|Hungary|Poland|Romania|Serbia 1
United States|Canada|Germany|Italy|Sweden|United Kingdom 1
United States|Canada|Puerto Rico|United Kingdom 1
United States|Czechia|United Kingdom 1
United States|Germany 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 68
2 9
3 5
4 2
5 1
6 1
7 4
8 2
9 1
10 3
12 2
13 1
14 1
16 1
17 1
18 1
21 1
23 1
24 2
26 2
29 2
30 3
31 1
32 1
40 1
43 1
44 1
52 2
57 1
58 1
59 1
63 1
64 1
66 1
69 1
84 1
90 1
99 1
109 1
117 2
187 1
427 1

Phase

Phase Study_Count
Phase 2 46
Phase 3 28
N/A 23
Phase 1 17
Phase 4 15
Phase 1/Phase 2 4
Phase 2/Phase 3 2
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 30
2 71
3 13
4 11
5 1
6 4
7 1
25 1
NA 4

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 12 5.0000 6.00000 10.00 10.0000 300.0 45.000 12.0000
1st Qu. 12 30.0000 20.00000 12.25 44.5000 322.5 191.000 42.0000
Median 12 100.0000 40.00000 31.50 104.5000 345.0 503.500 80.0000
Mean 12 469.7826 70.76471 43.75 160.0652 345.0 1131.607 283.2667
3rd Qu. 12 475.0000 100.00000 63.00 196.2500 367.5 644.000 245.0000
Max. 12 3000.0000 208.00000 102.00 944.0000 390.0 17525.000 2500.0000

Trial Group Type

group_type Group_Count
Experimental 184
Active Comparator 63
Placebo Comparator 46
Other 13
No Intervention 9
NA 4
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 95
Single Group Assignment 31
Crossover Assignment 4
Sequential Assignment 4
Factorial Assignment 1
NA 1

Primary Purpose

primary_purpose Study_Count
Treatment 83
Prevention 43
Basic Science 3
NA 3
Diagnostic 2
Other 2

Observational Studies

Studies by Country

Country Study_Count
United States 11
Spain 4
China 2
NA 2
Canada 1
Denmark 1
France 1
France|Germany|Greece|Netherlands|Romania|Spain 1
Germany 1
Greece 1
Japan 1
Korea, Republic of 1

Sites per Study

Site_count Study_Count
1 22
6 2
12 1
24 1
34 1

Enrollment Metrics

Measure Observational
Min 10.00
1st Qu 141.00
Median 450.00
Mean 17158.67
3rd Qu 1003.50
Max 204666.00

Observation Model

observational_model Study_Count
Cohort 8
Case-Only 6
Case-Control 5
Other 4
Case Control 2
NA 2

Time Perspective

time_perspective Study_Count
Prospective 17
Retrospective 6
Other 2
Cross-Sectional 1
NA 1

Registries

Studies by Country

Country Study_Count
United States 2
Hong Kong 1
Israel 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 3
3 1
33 1

Enrollment Metrics

Measure Registries
Min 75.0
1st Qu 200.0
Median 227.0
Mean 979.2
3rd Qu 394.0
Max 4000.0

Registry Model

observational_model Study_Count
Case-Only 2
Cohort 2
Other 1

Time Perspective

time_perspective Study_Count
Prospective 4
Other 1

Follow-up

target_duration Study_Count
10 Years 2
1 Month 1
1 Year 1
2 Weeks 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03030248 Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients https://ClinicalTrials.gov/show/NCT03030248 Recruiting Medical College of Wisconsin 2020-06-30
NCT03388268 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment https://ClinicalTrials.gov/show/NCT03388268 Active, not recruiting Washington University School of Medicine 2020-12-31
NCT03824795 Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD https://ClinicalTrials.gov/show/NCT03824795 Completed MGB Biopharma Limited 2020-04-03
NCT03268213 Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis https://ClinicalTrials.gov/show/NCT03268213 Active, not recruiting Stony Brook University 2022-06-30
NCT03200093 Oral Vancomycin for Preventing Clostridium Difficile Recurrence https://ClinicalTrials.gov/show/NCT03200093 Enrolling by invitation Rochester General Hospital 2020-06-30
NCT03183141 ECOSPOR IV: An Open-Label Extension of Study SERES 012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03183141 Enrolling by invitation Seres Therapeutics, Inc. 2020-02-29
NCT03183128 ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03183128 Active, not recruiting Seres Therapeutics, Inc. 2020-07-31
NCT03182907 Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) https://ClinicalTrials.gov/show/NCT03182907 Recruiting Merck Sharp & Dohme Corp. 2022-05-09
NCT03110133 Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff https://ClinicalTrials.gov/show/NCT03110133 Active, not recruiting Finch Research and Development LLC. 2020-02-28
NCT03107169 Treatment of Initial Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03107169 Completed Universidad Autonoma de Nuevo Leon 2015-09-30
NCT03106844 The ICON Study: Outcomes After FMT for Patients With IBD and CDI https://ClinicalTrials.gov/show/NCT03106844 Recruiting Brigham and Women’s Hospital 2020-06-30
NCT03005379 Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) https://ClinicalTrials.gov/show/NCT03005379 Active, not recruiting VA Office of Research and Development 2022-05-30
NCT02996487 Screening to Prophylax Against Clostridium Difficile Infection - https://ClinicalTrials.gov/show/NCT02996487 Recruiting William Beaumont Hospitals 2020-09-30
NCT02981316 Treatment of Recurrent Clostridium Difficile Infection With RBX7455 https://ClinicalTrials.gov/show/NCT02981316 Active, not recruiting Mayo Clinic 2020-11-30
NCT02951702 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics https://ClinicalTrials.gov/show/NCT02951702 Completed St. Luke’s Hospital, Chesterfield, Missouri 2017-05-31
NCT02865616 MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) https://ClinicalTrials.gov/show/NCT02865616 Recruiting NuBiyota 2019-12-15
NCT02857582 Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile https://ClinicalTrials.gov/show/NCT02857582 Completed Uppsala University 2018-10-31
NCT02784002 A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) https://ClinicalTrials.gov/show/NCT02784002 Completed Summit Therapeutics 2016-08-31
NCT02743234 Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT02743234 Completed University of Aarhus 2019-02-28
NCT02725437 Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults https://ClinicalTrials.gov/show/NCT02725437 Completed Pfizer 2017-02-28
NCT02692651 A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections https://ClinicalTrials.gov/show/NCT02692651 Recruiting University of Michigan 2021-01-31
NCT02592343 A Prospective Trial of Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT02592343 Active, not recruiting McMaster University 2020-01-31
NCT02589847 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT02589847 Completed Rebiotix Inc. 2017-06-30
NCT03595566 To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03595566 Recruiting Summit Therapeutics 2021-06-30
NCT02570477 FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment https://ClinicalTrials.gov/show/NCT02570477 Active, not recruiting Chinese University of Hong Kong 2018-01-31
NCT02134392 Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection https://ClinicalTrials.gov/show/NCT02134392 Recruiting Nationwide Children’s Hospital 2022-01-31
NCT02563106 A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI https://ClinicalTrials.gov/show/NCT02563106 Completed Synthetic Biologics Inc. 2016-11-30
NCT02561195 A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years https://ClinicalTrials.gov/show/NCT02561195 Completed Pfizer 2017-03-07
NCT02502682 Chlorhexidine Bathing Effect on Clostridium Difficile Rates https://ClinicalTrials.gov/show/NCT02502682 Completed Northwestern Medicine 2016-06-30
NCT02465463 Early FMT for C.Difficile https://ClinicalTrials.gov/show/NCT02465463 Completed Emory University 2016-11-30
NCT02440438 Host Immune Response to Clostridium Difficile Infection (ICD) https://ClinicalTrials.gov/show/NCT02440438 Completed Hospices Civils de Lyon 2016-08-31
NCT02437591 Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) https://ClinicalTrials.gov/show/NCT02437591 Completed Astellas Pharma Inc 2016-05-12
NCT02437487 SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) https://ClinicalTrials.gov/show/NCT02437487 Completed Seres Therapeutics, Inc. 2016-07-31
NCT02423967 Fresh Versus Frozen Stool for Fecal Transplant in Children https://ClinicalTrials.gov/show/NCT02423967 Completed Mayo Clinic 2019-03-04
NCT02395848 Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection https://ClinicalTrials.gov/show/NCT02395848 Recruiting McMaster University 2021-12-31
NCT02316470 Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study https://ClinicalTrials.gov/show/NCT02316470 Completed Valneva Austria GmbH 2015-05-31
NCT02301000 IMT for Primary Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT02301000 Active, not recruiting Oslo University Hospital 2020-10-31
NCT02299570 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT02299570 Completed Rebiotix Inc. 2016-01-31
NCT02269150 Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02269150 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-10-31
NCT02255305 FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI https://ClinicalTrials.gov/show/NCT02255305 Recruiting NorthShore University HealthSystem 2019-09-30
NCT02254967 A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population https://ClinicalTrials.gov/show/NCT02254967 Completed Astellas Pharma Inc 2016-03-27
NCT02218372 A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) https://ClinicalTrials.gov/show/NCT02218372 Completed Astellas Pharma Inc 2018-03-07
NCT02179658 A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD) https://ClinicalTrials.gov/show/NCT02179658 Completed Astellas Pharma Inc 2016-09-08
NCT02127814 Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile https://ClinicalTrials.gov/show/NCT02127814 Completed Case Western Reserve University 2014-08-31
NCT02127398 Stool Transplants to Treat Refractory Clostridium Difficile Colitis https://ClinicalTrials.gov/show/NCT02127398 Recruiting Duke University 2022-05-31
NCT02117570 A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine. https://ClinicalTrials.gov/show/NCT02117570 Completed Pfizer 2015-12-31
NCT02106338 Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123. https://ClinicalTrials.gov/show/NCT02106338 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2014-12-31
NCT02092935 A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) https://ClinicalTrials.gov/show/NCT02092935 Completed Summit Therapeutics 2015-10-31
NCT01296386 An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 https://ClinicalTrials.gov/show/NCT01296386 Completed Valneva Austria GmbH 2013-04-30
NCT01295918 Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children https://ClinicalTrials.gov/show/NCT01295918 Completed St Marina University Hospital, Varna, Bulgaria 2013-06-30
NCT02053181 Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT02053181 Completed Actelion 2012-09-30
NCT02052726 A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine. https://ClinicalTrials.gov/show/NCT02052726 Completed Pfizer 2015-05-02
NCT03353506 Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection https://ClinicalTrials.gov/show/NCT03353506 Completed University of Alberta 2019-06-05
NCT01946750 Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections https://ClinicalTrials.gov/show/NCT01946750 Completed Versailles Hospital 2016-06-30
NCT01925417 Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea https://ClinicalTrials.gov/show/NCT01925417 Completed Rebiotix Inc. 2014-03-31
NCT01914731 Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum https://ClinicalTrials.gov/show/NCT01914731 Completed Massachusetts General Hospital 2014-10-31
NCT01901276 Effects of Gastric Acid on Colonic Microbiome https://ClinicalTrials.gov/show/NCT01901276 Completed Columbia University 2015-03-31
NCT01822977 The Impact of Proton Pump Inhibitors on the Fecal Microbiome https://ClinicalTrials.gov/show/NCT01822977 Completed Mayo Clinic 2013-12-31
NCT01818141 Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin https://ClinicalTrials.gov/show/NCT01818141 Completed Hartford Hospital 2014-12-15
NCT01716533 Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI) https://ClinicalTrials.gov/show/NCT01716533 Completed GlaxoSmithKline 2015-06-01
NCT01706367 Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years https://ClinicalTrials.gov/show/NCT01706367 Completed Pfizer 2014-01-31
NCT01704937 Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum https://ClinicalTrials.gov/show/NCT01704937 Completed Massachusetts General Hospital 2014-05-31
NCT01691248 Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) https://ClinicalTrials.gov/show/NCT01691248 Completed Optimer Pharmaceuticals LLC 2015-03-18
NCT01680874 Probiotics for Clostridium Difficile Infection in Older Adults https://ClinicalTrials.gov/show/NCT01680874 Completed University of Wisconsin, Madison 2015-02-28
NCT01670149 Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea https://ClinicalTrials.gov/show/NCT01670149 Completed University of Nottingham 2016-07-31
NCT01598311 A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) https://ClinicalTrials.gov/show/NCT01598311 Completed Cubist Pharmaceuticals LLC 2015-07-26
NCT01597505 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) https://ClinicalTrials.gov/show/NCT01597505 Completed Cubist Pharmaceuticals LLC 2015-03-20
NCT01591863 Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) https://ClinicalTrials.gov/show/NCT01591863 Completed Optimer Pharmaceuticals LLC 2014-03-07
NCT03349268 Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection https://ClinicalTrials.gov/show/NCT03349268 Recruiting University of Michigan 2022-05-31
NCT01513239 A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) https://ClinicalTrials.gov/show/NCT01513239 Completed Merck Sharp & Dohme Corp. 2015-05-22
NCT01401023 Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD) https://ClinicalTrials.gov/show/NCT01401023 Completed Michigan State University 2013-07-31
NCT01398969 Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI https://ClinicalTrials.gov/show/NCT01398969 Completed McMaster University 2015-01-31
NCT04247542 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection https://ClinicalTrials.gov/show/NCT04247542 Recruiting Acurx Pharmaceuticals LLC 2021-07-31
NCT04090346 Fecal Microbiota Transplant https://ClinicalTrials.gov/show/NCT04090346 Enrolling by invitation Methodist Health System 2024-06-30
NCT04014413 Safety and Efficacy of Fecal Microbiota Transplantation https://ClinicalTrials.gov/show/NCT04014413 Recruiting Chinese University of Hong Kong 2023-10-31
NCT04003818 Efficacy and Safety of Teicoplanin in CDAD https://ClinicalTrials.gov/show/NCT04003818 Recruiting Sanofi 2022-04-30
NCT04000555 Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) https://ClinicalTrials.gov/show/NCT04000555 Recruiting University of South Florida 2020-06-30
NCT03988855 An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03988855 Recruiting Deinove 2020-06-05
NCT03973697 Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03973697 Active, not recruiting University of Pennsylvania 2021-07-31
NCT03970200 PMT for Severe-CDI https://ClinicalTrials.gov/show/NCT03970200 Active, not recruiting University of Pennsylvania 2021-07-31
NCT03931941 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) https://ClinicalTrials.gov/show/NCT03931941 Recruiting Rebiotix Inc. 2020-04-30
NCT03925636 Specific Carbohydrate Diet for Clostridium Difficile https://ClinicalTrials.gov/show/NCT03925636 Recruiting Seattle Children’s Hospital 2022-01-01
NCT03918629 Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study https://ClinicalTrials.gov/show/NCT03918629 Recruiting Pfizer 2020-06-09
NCT03880539 Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03880539 Recruiting University of Kansas Medical Center 2020-09-30
NCT03857464 C Difficile Near-patient Diagnostics https://ClinicalTrials.gov/show/NCT03857464 Recruiting University of Calgary 2020-02-15
NCT03834038 Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03834038 Active, not recruiting Vancouver Island Health Authority 2019-06-30
NCT03829475 ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI https://ClinicalTrials.gov/show/NCT03829475 Recruiting Brigham and Women’s Hospital 2021-06-01
NCT03827447 Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile https://ClinicalTrials.gov/show/NCT03827447 Recruiting Medical College of Wisconsin 2021-06-01
NCT03806803 Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection https://ClinicalTrials.gov/show/NCT03806803 Recruiting University of Alberta 2021-03-31
NCT03804736 Fecal Microbiota Transplant by Oral Capsules With Lactobacilli for Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03804736 Active, not recruiting Universidad Autonoma de Nuevo Leon 2018-06-30
NCT03796650 Fecal Transplantation for Primary Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03796650 Recruiting Oslo University Hospital 2024-01-31
NCT03788434 Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03788434 Recruiting Vedanta Biosciences, Inc. 2020-12-31
NCT03778606 Oligosaccharide for Cdiff(+) Heme-onc Patients https://ClinicalTrials.gov/show/NCT03778606 Recruiting Medical College of Wisconsin 2020-06-01
NCT03760484 Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03760484 Recruiting University of Alberta 2021-12-16
NCT03710694 Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI) https://ClinicalTrials.gov/show/NCT03710694 Completed Da Volterra 2019-08-09
NCT03617172 PROCLAIM – Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol https://ClinicalTrials.gov/show/NCT03617172 Recruiting Vanderbilt University Medical Center 2022-11-30
NCT03579459 Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age https://ClinicalTrials.gov/show/NCT03579459 Completed Pfizer 2019-08-06
NCT03562741 Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile https://ClinicalTrials.gov/show/NCT03562741 Recruiting University of Massachusetts, Worcester 2022-01-16
NCT03548051 Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD) https://ClinicalTrials.gov/show/NCT03548051 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2021-09-06
NCT03497806 Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03497806 Enrolling by invitation Finch Research and Development LLC. 2020-02-01
NCT03466502 Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics https://ClinicalTrials.gov/show/NCT03466502 Enrolling by invitation University of Nevada, Reno 2020-03-31
NCT03462459 Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03462459 Recruiting University of Wisconsin, Madison 2021-12-31
NCT03427229 Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03427229 Completed Catholic University of the Sacred Heart 2017-10-30
NCT01259726 Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT01259726 Completed Shire 2013-06-30
NCT01241552 A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) https://ClinicalTrials.gov/show/NCT01241552 Completed Merck Sharp & Dohme Corp. 2014-12-09
NCT01232595 Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections https://ClinicalTrials.gov/show/NCT01232595 Completed Novartis 2013-07-31
NCT01230957 Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults https://ClinicalTrials.gov/show/NCT01230957 Completed Sanofi 2012-11-30
NCT01222702 Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD) https://ClinicalTrials.gov/show/NCT01222702 Completed Actelion 2012-10-16
NCT01087892 Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT01087892 Completed University of Sussex 2013-09-30
NCT01085591 Study of CB-183,315 in Participants With Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT01085591 Completed Cubist Pharmaceuticals LLC 2011-04-13
NCT00958308 Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection https://ClinicalTrials.gov/show/NCT00958308 Completed Bio-K Plus International Inc. 2009-03-31
NCT04012788 CDI Synbiotic Study https://ClinicalTrials.gov/show/NCT04012788 Recruiting Hvidovre University Hospital 2020-05-01
NCT01987895 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea https://ClinicalTrials.gov/show/NCT01987895 Completed Actelion 2017-02-26
NCT01983683 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea https://ClinicalTrials.gov/show/NCT01983683 Completed Actelion 2017-03-09
NCT01896830 Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan https://ClinicalTrials.gov/show/NCT01896830 Completed Sanofi 2013-10-31
NCT04026009 Study of GlaxoSmithKline’s (GSK) Clostridium Difficile Vaccine to Investigate the Safety and Ability to Provoke an Immune Response in the Body When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years https://ClinicalTrials.gov/show/NCT04026009 Recruiting GlaxoSmithKline 2021-07-13
NCT03244644 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) https://ClinicalTrials.gov/show/NCT03244644 Active, not recruiting Rebiotix Inc. 2020-06-30
NCT03090191 Clostridium Difficile Vaccine Efficacy Trial https://ClinicalTrials.gov/show/NCT03090191 Active, not recruiting Pfizer 2020-09-28
NCT03595553 Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT03595553 Recruiting Summit Therapeutics 2021-06-30
NCT01905709 Fecal Microbiota Transplantation for C Diff Infection https://ClinicalTrials.gov/show/NCT01905709 Recruiting Englewood Hospital and Medical Center 2020-07-31
NCT04121169 Treatment of Mild-moderate Clostridium Difficile Infection (CDI) https://ClinicalTrials.gov/show/NCT04121169 Recruiting ImmuniMed Inc. 2020-09-30
NCT02968758 Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains https://ClinicalTrials.gov/show/NCT02968758 Completed GenePOC 2017-08-02
NCT00772343 Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFFâ„¢) in Subjects With Clostridium Difficile Infection https://ClinicalTrials.gov/show/NCT00772343 Completed Sanofi 2011-07-31
NCT00566306 Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation https://ClinicalTrials.gov/show/NCT00566306 Completed University of Helsinki 2008-06-30
NCT00563186 Hospital Design and Risk of Nosocomial Infections: A Prospective Controlled Trial https://ClinicalTrials.gov/show/NCT00563186 Completed University of Calgary 2010-02-28
NCT00468728 PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) https://ClinicalTrials.gov/show/NCT00468728 Completed Optimer Pharmaceuticals LLC 2009-12-11
NCT00417872 Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis https://ClinicalTrials.gov/show/NCT00417872 Completed Romark Laboratories L.C. NA
NCT00382304 A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea https://ClinicalTrials.gov/show/NCT00382304 Completed Sanofi NA
NCT00350298 Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease https://ClinicalTrials.gov/show/NCT00350298 Completed MassBiologics 2008-07-31
NCT00328263 Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients https://ClinicalTrials.gov/show/NCT00328263 Completed Bio-K Plus International Inc. 2007-03-31
NCT00269399 A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) https://ClinicalTrials.gov/show/NCT00269399 Completed Bausch Health Americas, Inc. 2008-12-31
NCT00214461 Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers https://ClinicalTrials.gov/show/NCT00214461 Completed Sanofi 2006-02-28
NCT00130221 Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections https://ClinicalTrials.gov/show/NCT00130221 Completed John H. Stroger Hospital NA
NCT00127803 Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT00127803 Completed Sanofi 2006-01-31
NCT00034294 A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea https://ClinicalTrials.gov/show/NCT00034294 Completed Sanofi NA
NCT00314951 Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018) https://ClinicalTrials.gov/show/NCT00314951 Completed Optimer Pharmaceuticals LLC 2008-07-23

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03250104 Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives https://ClinicalTrials.gov/show/NCT03250104 Recruiting University Hospital of Cologne 2018-12-31
NCT03025672 Evaluation of the Cost of a Nosocomial Infection With Clostridium Difficile https://ClinicalTrials.gov/show/NCT03025672 Completed Lille Catholic University 2017-01-31
NCT02133651 Mucosal Versus Fecal Microbiota in FMT https://ClinicalTrials.gov/show/NCT02133651 Completed Emory University 2015-08-31
NCT02896244 AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment https://ClinicalTrials.gov/show/NCT02896244 Completed UMC Utrecht 2018-01-23
NCT02573571 Personalized Needs in Clostridium Difficile Infections https://ClinicalTrials.gov/show/NCT02573571 Completed University of Athens 2016-12-31
NCT02327520 Clostridium Difficile Infection: the First Report in Southeast Asia by 2010 Nationwide Study https://ClinicalTrials.gov/show/NCT02327520 Completed King Chulalongkorn Memorial Hospital 2010-12-31
NCT02223715 Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries https://ClinicalTrials.gov/show/NCT02223715 Completed Otsuka Pharmaceutical Co., Ltd. 2015-01-31
NCT02214771 Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients https://ClinicalTrials.gov/show/NCT02214771 Completed Astellas Pharma Inc 2017-03-27
NCT01957761 Molecular Epidemiology of Clostridium Difficile Infections in Children https://ClinicalTrials.gov/show/NCT01957761 Completed Ann & Robert H Lurie Children’s Hospital of Chicago 2014-06-30
NCT01930032 Pathogenic Mechanisms in C Diff Infection and Colitis https://ClinicalTrials.gov/show/NCT01930032 Completed Beth Israel Deaconess Medical Center 2014-01-31
NCT01813500 Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients https://ClinicalTrials.gov/show/NCT01813500 Completed Boston Medical Center 2015-09-30
NCT01560832 Descriptive Epidemiology of Clostridium Difficile Infection in Hospitalized Adult Patients in the Asia Pacific Region https://ClinicalTrials.gov/show/NCT01560832 Completed Yonsei University 2012-06-30
NCT04317963 Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection https://ClinicalTrials.gov/show/NCT04317963 Enrolling by invitation University of Illinois at Chicago 2021-05-31
NCT04187430 Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies https://ClinicalTrials.gov/show/NCT04187430 Recruiting Hospital General Universitario Gregorio Marañon 2020-06-15
NCT04179201 Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease https://ClinicalTrials.gov/show/NCT04179201 Recruiting Xijing Hospital 2020-01-31
NCT04100603 A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection https://ClinicalTrials.gov/show/NCT04100603 Recruiting ProgenaBiome 2023-03-31
NCT04075422 Bezlotoxumab - in “Real Life” - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence. https://ClinicalTrials.gov/show/NCT04075422 Recruiting Fundacion SEIMC-GESIDA 2021-03-15
NCT04070352 Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI) https://ClinicalTrials.gov/show/NCT04070352 Active, not recruiting University of Pittsburgh 2024-12-31
NCT04014608 Protocol for Admission Toxigenic C. Difficile Surveillance https://ClinicalTrials.gov/show/NCT04014608 Completed NorthShore University HealthSystem 2016-12-31
NCT03964844 Clostridium Difficile Infection (CDI) in Hematologic Patients. https://ClinicalTrials.gov/show/NCT03964844 Recruiting Hospital General Universitario Gregorio Marañon 2019-12-31
NCT03895593 Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections https://ClinicalTrials.gov/show/NCT03895593 Recruiting The Second Hospital of Nanjing Medical University 2024-05-01
NCT03889808 Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients. https://ClinicalTrials.gov/show/NCT03889808 Recruiting Hospital Universitari de Bellvitge 2021-01-31
NCT03848689 FQ Restriction for the Prevention of CDI https://ClinicalTrials.gov/show/NCT03848689 Enrolling by invitation University of Wisconsin, Madison 2023-02-28
NCT03712722 Fecal Microbiota Transplantation (FMT) for Clostridium Difficile https://ClinicalTrials.gov/show/NCT03712722 Recruiting University of Aarhus 2023-12-31
NCT01066221 Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile https://ClinicalTrials.gov/show/NCT01066221 Completed McMaster University 2010-03-31
NCT00446355 Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes https://ClinicalTrials.gov/show/NCT00446355 Completed University of Pittsburgh 2009-04-30
NCT00304369 Response of Clostridium Difficile Infection to Metronidazole Therapy https://ClinicalTrials.gov/show/NCT00304369 Completed VA Medical Center, Houston 2007-06-30

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03325855 Fecal Microbiota Transplant National Registry https://ClinicalTrials.gov/show/NCT03325855 Recruiting American Gastroenterological Association 2021-08-31
NCT03117582 Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics https://ClinicalTrials.gov/show/NCT03117582 Enrolling by invitation University of North Carolina, Chapel Hill 2026-12-31
NCT02063282 The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers https://ClinicalTrials.gov/show/NCT02063282 Completed Shaare Zedek Medical Center 2014-12-31
NCT03350711 A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program https://ClinicalTrials.gov/show/NCT03350711 Recruiting Emory University 2028-01-31
NCT03654872 Clostridium Difficile Virulence Mechanism Study (CDVM Study) https://ClinicalTrials.gov/show/NCT03654872 Recruiting Chinese University of Hong Kong 2019-05-30